AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
prednisolone succinate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| prednisone and prednisolone derivatives | 2246 | 2920-86-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 0.22 mg/mL | Bocci G, Oprea TI, Benet LZ |
| CL (Clearance) | 1.46 mL/min/kg | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
| BA (Bioavailability) | 82 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 0.853 | Moderate | 0.70 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | Moderate | 0.70 | |
| rat-kpuu-brain | Rat brain Kpuu | 0.011 | % | Moderate | 0.70 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxic epidermal necrolysis | 183.95 | 47.31 | 49 | 1162 | 32479 | 90594757 |
| Stevens-Johnson syndrome | 79.50 | 47.31 | 25 | 1186 | 29351 | 90597885 |
| Lip erosion | 73.75 | 47.31 | 13 | 1198 | 1225 | 90626011 |
| Cholecystitis | 56.67 | 47.31 | 17 | 1194 | 17023 | 90610213 |
| Conjunctivitis | 53.06 | 47.31 | 18 | 1193 | 26688 | 90600548 |
| Circulatory collapse | 50.32 | 47.31 | 17 | 1194 | 24887 | 90602349 |
| Dermatitis exfoliative | 49.20 | 47.31 | 12 | 1199 | 5524 | 90621712 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxic epidermal necrolysis | 169.07 | 30.57 | 61 | 2771 | 56666 | 110529801 |
| Stevens-Johnson syndrome | 74.41 | 30.57 | 32 | 2800 | 46869 | 110539598 |
| Lip erosion | 65.60 | 30.57 | 14 | 2818 | 1852 | 110584615 |
| Polyneuropathy | 61.36 | 30.57 | 25 | 2807 | 31987 | 110554480 |
| Cholecystitis | 42.15 | 30.57 | 18 | 2814 | 25864 | 110560603 |
| Pneumonia | 40.88 | 30.57 | 77 | 2755 | 876637 | 109709830 |
| Conjunctivitis | 40.62 | 30.57 | 19 | 2813 | 33773 | 110552694 |
| Hyperthyroidism | 40.02 | 30.57 | 18 | 2814 | 29243 | 110557224 |
| Pneumothorax | 39.83 | 30.57 | 19 | 2813 | 35266 | 110551201 |
| Blister | 33.75 | 30.57 | 35 | 2797 | 227341 | 110359126 |
| Multiple organ dysfunction syndrome | 33.29 | 30.57 | 29 | 2803 | 151681 | 110434786 |
| Dermatitis exfoliative | 32.96 | 30.57 | 12 | 2820 | 11335 | 110575132 |
| Lymphocytosis | 32.95 | 30.57 | 10 | 2822 | 5401 | 110581066 |
| Respiratory disorder | 32.16 | 30.57 | 21 | 2811 | 71361 | 110515106 |
| Circulatory collapse | 30.68 | 30.57 | 17 | 2815 | 42976 | 110543491 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA MoA | N0000175450 | Corticosteroid Hormone Receptor Agonists |
| FDA EPC | N0000175576 | Corticosteroid |
| MeSH PA | D005938 | Glucocorticoids |
| MeSH PA | D006728 | Hormones |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D018931 | Antineoplastic Agents, Hormonal |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:33231 | antitubercular agent |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:35472 | anti-inflammatory drug |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
| CHEBI has role | CHEBI:35703 | xenobiotic |
| CHEBI has role | CHEBI:35705 | immunosuppressive agent |
| CHEBI has role | CHEBI:35816 | leprostatic drug |
| CHEBI has role | CHEBI:35842 | antirheumatic drug |
| CHEBI has role | CHEBI:37962 | adrenergic agent |
| CHEBI has role | CHEBI:39456 | antiglaucoma drug |
| CHEBI has role | CHEBI:49103 | drug metabolite |
| CHEBI has role | CHEBI:49201 | anti-ulcer drug |
| CHEBI has role | CHEBI:50177 | dermatologic drug |
| CHEBI has role | CHEBI:50671 | antithyroid drug |
| CHEBI has role | CHEBI:50748 | antipsoriatic |
| CHEBI has role | CHEBI:53784 | antispasmodic drug |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
| CHEBI has role | CHEBI:65023 | anti-asthmatic agent |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:76595 | nephroprotective agent |
| CHEBI has role | CHEBI:77715 | nasal decongestant |
| CHEBI has role | CHEBI:78298 | environmental contaminant |
| CHEBI has role | CHEBI:231911 | renoprotective agent |
| CHEBI has role | CHEBI:233423 | antifibrotic agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Inflammation | Indication |
| Cats | Allergy and less severe stress conditions | Indication |
| Dogs | Inflammation | Indication |
| Dogs | Allergy and less severe stress conditions | Indication |
| Dogs | Shock | Indication |
| Horses | Inflammation | Indication |
| Horses | Allergy | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Solu-Delta Cortef Sterile Powder | Zoetis Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.23 | acidic |
| pKa2 | 12.65 | acidic |
| pKa3 | 13.36 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D02156 | KEGG_DRUG |
| 4017988 | VANDF |
| C0071840 | UMLSCUI |
| TUA | PDB_CHEM_ID |
| CHEMBL485659 | ChEMBL_ID |
| DB14633 | DRUGBANK_ID |
| C021322 | MESH_SUPPLEMENTAL_RECORD_UI |
| 656804 | PUBCHEM_CID |
| 55063 | RXNORM |
| 5347 | MMSL |
| 59710 | MMSL |
| d00084 | MMSL |
| 002155 | NDDF |
| 002158 | NDDF |
| 006890 | NDDF |
| 1013811000202101 | SNOMEDCT_US |
| 116601002 | SNOMEDCT_US |
| 52388000 | SNOMEDCT_US |
| C0032950 | UMLSCUI |
| CHEBI:135745 | CHEBI |
| CHEMBL1412530 | ChEMBL_ID |
| DB00860 | DRUGBANK_ID |
| 1715-33-9 | SECONDARY_CAS_RN |
| 5755 | PUBCHEM_CID |
| 535 | INN_ID |
| D011239 | MESH_DESCRIPTOR_UI |
| G7080T74ON | UNII |
| CHEBI:8378 | CHEBI |
| G7080T74ON | INXIGHT DRUGS |
Pharmaceutical products:
None